SF-1126

N/A

Report date: 2022/08/22 14:48:10
NME

Base Information

Drug NameSF-1126
Drug Alias NamePI3K pan inhibitor - SignalRx PharmaceuticalsSF-1126CC-1126
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionPI3-kinase class I inhibitorsmTOR Complex 2 inhibitorsMammalian target of Rapamycin (mTORC1) inhibitors
TargetsMammalian target of Rapamycin (mTORC1)mTOR Complex 2PI3-kinase class I
Therapy Area/IndicationsSolid tumoursCarcinoma, Squamous CellCarcinoma, Hepatocellular +[5] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusDiscontinued (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesSignalrx Pharmaceuticals Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesSignalrx Pharmaceuticals IncSemafore Pharmaceuticals Inc
Active IndicationsN/A
Inactive IndicationsSolid tumoursCarcinoma, Squamous CellCarcinoma, Hepatocellular +[5] 

Other Information

ATC CodeN/A
Related LinksDrugBank